Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML

NCT04676243 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Study turned out no longer feasible

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Quizartinib
DRUG: Treatment according to Physician's Choice
DRUG: Standard of Care Chemotherapy

Sponsor

University Hospital Heidelberg

Collaborators

[object Object]